In Vivo Model Development for Graft-Versus-Host Disease

Protheragen offers a comprehensive in vivo animal model development service focused on Graft-Versus-Host Disease (GVHD) research and therapeutic evaluation. Our service is designed to support academic, biotech, and pharmaceutical partners with robust, clinically relevant models that accelerate the discovery and validation of novel GVHD therapies. Leveraging a diverse repertoire of animal species and transplantation techniques, we deliver tailored preclinical solutions that address a wide spectrum of scientific and translational needs.

Graft-Versus-Host Disease is a critical complication following allogeneic tissue or cell transplantation, particularly in the context of hematopoietic stem cell transplantation. Preclinical animal models are essential for unraveling the immunopathology of GVHD and for evaluating the safety and efficacy of candidate interventions prior to clinical application. At Protheragen, we utilize a broad range of species—including mice (Mus musculus), rats (Rattus norvegicus), dogs (Canis familiaris), non-human primates (Macaca fascicularis, Macaca mulatta, Papio anubis), and minipigs—to model diverse aspects of GVHD. Our models encompass various genetic backgrounds, immune deficiencies, and transplantation scenarios (allograft, xenograft, syngeneic), closely mirroring the complexity and heterogeneity of human GVHD. This breadth enables us to support both mechanistic studies and translational research, facilitating the development of interventions with high clinical relevance.

Allogeneic Transplantation Models

Allogeneic transplantation models are the gold standard for GVHD research and involve the transfer of hematopoietic stem cells, bone marrow cells, or solid organs between genetically distinct donors and recipients of the same species. Methodologies include irradiation or immunosuppression of the recipient to facilitate engraftment, followed by infusion of donor-derived cells (e.g., bone marrow, splenocytes, T-lymphocytes). Key advantages include strong recapitulation of human GVHD immunopathology and flexibility in manipulating donor/recipient strain combinations (e.g., MHC-matched or mismatched, T-cell depletion, knockout or transgenic lines). These models are primarily used for mechanistic studies, efficacy testing of immunosuppressive agents, and evaluation of cellular therapies.

Xenogeneic Transplantation Models

Xenogeneic models involve transplantation of cells or tissues across species barriers, such as human peripheral blood mononuclear cells or hematopoietic stem cells into immunodeficient mice (e.g., NSG, NOG, BRGS). The methodology typically includes irradiation or genetic immunosuppression of the host to prevent rejection and allow human cell engraftment, followed by monitoring for GVHD manifestations. Advantages include the ability to study human immune cell function and human-specific therapeutic responses in vivo. These models are highly valuable for testing human-targeted biologics, gene therapies, and for bridging the translational gap between murine and clinical studies.

Genetically Modified and Immunodeficient Models

Genetically engineered and immunodeficient models (e.g., SCID, Rag1-/-, Il2rg-knockout, transgenic or knockout lines) provide unique platforms for dissecting immune cell contributions to GVHD and for supporting engraftment of donor tissues or human cells. Methodologies include targeted gene editing or selective breeding to generate mice with specific immune deficiencies or reporter genes. These models offer precise control over the immune landscape, enabling detailed mechanistic studies, tracking of cell subsets, and evaluation of gene- or cell-based therapies. Applications include fundamental immunology research, testing of immune modulation strategies, and validation of novel therapeutic targets.

Solid Organ and Tissue Graft Models

Solid organ (e.g., kidney, heart, skin, liver) and tissue graft models extend GVHD research beyond hematopoietic transplantation, enabling investigation of organ-specific immune responses and chronic rejection. Methodologies involve surgical transplantation of donor organs or tissues, often combined with irradiation or immunosuppression. Advantages include the ability to study acute and chronic graft rejection, tissue-specific GVHD manifestations, and the efficacy of anti-rejection therapies. These models are essential for preclinical evaluation of immunosuppressants, tolerance induction protocols, and regenerative medicine approaches.

Protheragen delivers a full-spectrum GVHD animal model development service, from model design and animal procurement to transplantation, monitoring, and comprehensive data analysis. Our solutions include: selection of optimal species and strains, irradiation or immunosuppression protocols, precise cell or tissue transplantation, and advanced post-transplant care. Key efficacy endpoints include survival analysis, clinical GVHD scoring (weight loss, skin changes, diarrhea, activity), histopathology of target organs (liver, gut, skin), immune cell profiling (flow cytometry, immunohistochemistry), cytokine quantification, and molecular biomarker analysis. Our analytical capabilities span multi-parameter flow cytometry, ELISA, multiplex cytokine assays, PCR, imaging (bioluminescence, histology), and next-generation sequencing. Quality control is ensured through standardized protocols, rigorous animal welfare compliance, and detailed data documentation, guaranteeing reproducibility and scientific integrity.

By partnering with Protheragen, you gain access to unparalleled expertise in GVHD animal modeling, a broad portfolio of validated models, and a dedicated team committed to accelerating your research. Our integrated approach ensures that your studies are scientifically robust, clinically relevant, and tailored to your therapeutic goals. Contact us today to discuss how our in vivo GVHD model development services can advance your preclinical pipeline and support your journey toward innovative GVHD therapies.